The ASGR1 Knockout KYSE-30 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the KYSE-30 human esophageal squamous cell carcinoma cell line. This product features targeted disruption of the ASGR1 gene, which encodes the major subunit of the asialoglycoprotein receptor. The polyclonal format comprises a heterogeneous pool of edited cells generated by CRISPR/Cas9-mediated gene disruption, providing a loss-of-function model for investigating ASGR1-dependent processes. This knockout cell population is designed for researchers studying glycoprotein homeostasis, receptor-mediated endocytosis, and ASGR1-linked signaling in a cancer cell context.
KYSE-30 cells are a widely utilized human esophageal squamous cell carcinoma line originating from a well-differentiated invasive tumor resected from a 64-year-old male patient. This cell line retains characteristic features of esophageal squamous cell carcinoma, including epithelial morphology and relevant oncogenic signaling networks, making it a robust in vitro model for studying tumor biology, therapeutic response, and metastasis. The genetic background of KYSE-30 provides a clinically relevant context for exploring the roles of genes such as ASGR1 that are typically associated with hepatic function but may have uncharacterized contributions to tumorigenesis in non-hepatic tissues.
ASGR1 encodes the major subunit (HL-1) of the asialoglycoprotein receptor, a C-type lectin that clears desialylated glycoproteins via clathrin-mediated endocytosis. Transcription is regulated by HNF4A, CEBPA, and STAT3. The receptor forms a complex with ASGR2 and utilizes AP2 and clathrin to internalize ligands like asialoorosomucoid, with dynamin and endosomal components mediating subsequent trafficking. ASGR1 knockout disrupts this pathway, potentially causing LDLR upregulation and altered glycoprotein homeostasis, although effects in esophageal carcinoma cells warrant further investigation.
Within the KYSE-30 esophageal squamous cell carcinoma background, ASGR1 knockout offers a unique platform to dissect the receptor??s role outside the liver, where its expression may influence glycoprotein scavenging, cell-surface glycosylation patterns, and metabolic adaptation. Because ASGR1-mediated endocytosis can affect cellular nutrient sensing and lipoprotein metabolism, its disruption may alter growth signaling or stress responses in cancer cells. This model thus enables the functional annotation of a traditionally hepatocentric gene in an epithelial tumor setting, potentially revealing novel vulnerabilities or modulatory effects on canonical cancer pathways.
Researchers can employ the ASGR1 Knockout KYSE-30 Polyclonal Cells in a variety of experimental workflows, including ligand uptake assays using fluorescent asialoorosomucoid to quantify endocytic activity, co-immunoprecipitation to examine receptor complex assembly, flow cytometry to assess surface expression or glycoprotein binding, and cell proliferation assays to evaluate growth effects. These cells are suitable for functional genomics studies of liver-related genes in non-hepatic contexts, drug delivery investigations targeting ASGR1-mediated internalization, and the exploration of ASGR1-dependent metabolic alterations in esophageal cancer. For additional information or technical support regarding this ASGR1 knockout model, please contact Ascent Research.
